Clinical Trials
60
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)⢠Click on a phase to view related trials
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
- Conditions
- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)Drug: Placebo to match CK-4021586
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 60
- Registration Number
- NCT06793371
- Locations
- đşđ¸
FOMAT - Comprehensive Cardiovascular Care, Santa Maria, California, United States
đşđ¸Cleveland Clinic Florida, Weston, Florida, United States
đşđ¸Eastern Shore Research Institute, LLC, Fairhope, Alabama, United States
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
- Conditions
- Heart FailureHeart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Omecamtiv Mecarbil (OM)Drug: Placebo
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 1800
- Registration Number
- NCT06736574
- Locations
- đşđ¸
The Queen's Medical Center - Punchbowl, Honolulu, Hawaii, United States
đşđ¸Northwell Health North Shore University Hospital, Manhasset, New York, United States
đşđ¸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
- Conditions
- PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-11-12
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 55
- Registration Number
- NCT06412666
- Locations
- đşđ¸
Phoenix Children's Hospital, Phoenix, Arizona, United States
đşđ¸Children's Hospital Los Angeles, Los Angeles, California, United States
đşđ¸University of California, Los Angeles (UCLA), Los Angeles, California, United States
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
- Conditions
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 500
- Registration Number
- NCT06081894
- Locations
- đşđ¸
Keck Medical Center of USC (Outpatient Clinic), Los Angeles, California, United States
đşđ¸UCLA Medical Center Cardiovascular Clinic, Los Angeles, California, United States
đşđ¸Northwell Health North Shore University Hospital, Manhasset, New York, United States
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 44
- Registration Number
- NCT05924815
- Locations
- đşđ¸
Celerion, Inc 2420, Tempe, Arizona, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
Imbria Pharmaceuticals Partners with Patient Advocacy Group to Accelerate Recruitment for Novel Heart Disease Trial
Imbria Pharmaceuticals has partnered with the Hypertrophic Cardiomyopathy Association to accelerate patient recruitment for the FORTITUDE-HCM Phase 2b trial evaluating ninerafaxstat in non-obstructive hypertrophic cardiomyopathy.
Cytokinetics Raises $650 Million Through Convertible Notes to Fund Aficamten Commercial Launch
Cytokinetics successfully priced an upsized $650 million convertible senior notes offering, increasing from the initially proposed $550 million to support aficamten's potential commercial launch.
Hengrui Licenses Heart Disease Drug HRS-1893 to Braveheart Bio for $65M Upfront, Potential $1B+ Total
Jiangsu Hengrui Pharmaceuticals has licensed its selective myosin blocker HRS-1893 to Delaware-based startup Braveheart Bio for $65 million upfront plus potential milestone payments exceeding $1 billion.
Braveheart Bio Raises $185M Series A to Advance Hypertrophic Cardiomyopathy Drug Licensed from Hengrui
Braveheart Bio secured $185 million in Series A funding to develop BHB-1893, a cardiac myosin inhibitor licensed from China's Hengrui Pharma for treating hypertrophic cardiomyopathy.
Heart Failure Pipeline Shows Strong Growth with 75+ Therapies in Development Across 70+ Companies
DelveInsight's 2025 pipeline analysis reveals a robust heart failure therapeutic landscape with over 70 companies developing 75+ pipeline therapies across various stages of clinical development.
Cytokinetics' Aficamten Shows Positive Results in MAPLE-HCM Trial for Hypertrophic Cardiomyopathy
Aficamten, Cytokinetics' cardiac myosin inhibitor, met its primary endpoint in the Phase 3 MAPLE-HCM trial, demonstrating significant improvement in peak oxygen uptake in obstructive hypertrophic cardiomyopathy patients.
Biopharma Q1 Updates: New Drug Launches and FDA Extension for Cytokinetics' Aficamten
Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.
Haya Therapeutics Secures $65M to Develop Drugs Targeting the 'Dark Genome'
⢠Haya Therapeutics has raised $65 million in Series A funding to develop therapeutics targeting long non-coding RNAs in the previously dismissed "junk DNA" regions of the human genome. ⢠The company's lead candidate, HTX-100, targets a long non-coding RNA called "Wisper" that plays a central role in non-obstructive hypertrophic cardiomyopathy, with clinical trials expected to begin soon. ⢠Unlike competitors' approaches that focus on reducing heart contractions, Haya's technology aims to address the underlying disease mechanisms by suppressing fibrosis and reprogramming disease-driving cell states.
Cytokinetics to Present New Aficamten Data at ACC 2025: Insights on Metabolism, Combination Therapy, and Long-Term Cardiac Effects
Cytokinetics will present five studies on aficamten at the upcoming ACC Scientific Session, including new data on its metabolism pathways through multiple CYP enzymes and the safety of combination therapy with disopyramide.
Cardiomyopathy Market Projected to Reach $20+ Billion by 2035 as Novel Therapies Advance Through Clinical Development
The global cardiomyopathy market is expected to grow at a CAGR of 6.13% from 2025-2035, driven by rising cardiovascular disease prevalence and innovative therapeutic developments.